Personalized Weight Lose Care in Maryland
How Obesity Can Increase Small LDL Particle Number
Obesity often increases the number of small LDL particles, which are more harmful than standard LDL cholesterol. These tiny particles stay longer in circulation, oxidize easily, and fuel artery plaque. Insulin resistance, high triglycerides, low HDL cholesterol, and inflammation all contribute. Advanced lipid testing reveals these hidden risks. Personalized care can reduce weight, improve insulin sensitivity, and shift cholesterol toward a safer pattern for heart health.
Published
Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care
Retatrutide is a triple hormone agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 trials show up to 24% weight loss, major A1c reduction, and liver fat improvement. This blog reviews trial findings and explains how they may influence our holistic, individualized approach to obesity and diabetes in Montgomery County, Maryland and beyond.
Published
Categorized as Diabetes Care, Dr. Tashko’s Key Clinical Trials, Insights from Dr. Tashko, Obesity Care, Weight Loss
Could a Stomach Virus Mimic GLP-1 Agonists?
A curious observation comes up now and then in clinic: a patient with a viral GI illness—typically marked by nausea, loss of appetite, and sometimes transient weight loss—describes symptoms eerily similar to what we see in GLP-1 agonist use. What’s driving this overlap?
Published
How Obesity Causes Chronic Kidney Disease
Obesity is a major risk factor for chronic kidney disease (CKD), damaging the kidneys through metabolic disturbances, increased kidney workload, inflammation, and structural changes. These interconnected processes accelerate kidney dysfunction, increasing the risk of kidney failure.
Published
Can GLP-1 Agonists Improve Taste Sensitivity?
GLP-1 agonists like Tirzepatide (Mounjaro, Zepbound) and Semaglutide (Ozempic, Wegovy) have become powerful tools in weight management. Their well-known benefits include reducing hunger, curbing cravings, and improving blood sugar regulation. But could they also enhance taste sensitivity and indirectly contribute to healthier eating habits?
Published
How GLP-1 Receptor Agonists Benefit Kidney and Heart Health
GLP-1 receptor agonists have transformed type 2 diabetes care. They lower blood sugar, reduce cardiovascular risks, and now show promise for kidney health. A recent Lancet meta-analysis highlights these benefits, offering insights into how these medications can protect vital organs.
Published
Categorized as Diabetes Care, Dr. Tashko’s Key Clinical Trials, GLP1 agonist, Heart Health, Kidney Health
SURMOUNT-1 Trial: Tirzepatide for Treating Obesity and Preventing Diabetes
Tirzepatide has emerged as a game-changing treatment for obesity and diabetes prevention. This three-year study, an extension of the SURMOUNT-1 trial, highlights its ability to deliver sustained weight loss and significantly lower the risk of type 2 diabetes in individuals with both obesity and prediabetes.
Published